

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 26 MAY 2025

Reference is made to the circular (“**Circular**”) and the notice (“**Notice**”) of Extraordinary general meeting (“**EGM**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) both dated 8 May 2025. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

EXTRAORDINARY GENERAL MEETING

At the EGM held on 26 May 2025 all the proposed resolutions as set out in the Notice were taken by poll.

As at the date of the EGM, the total number of issued shares of the Company (the “**Shares**”) was 2,032,890,585 Shares, which was the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the EGM. There were no treasury shares held by the Company (including any treasury shares held or deposited with the CCASS) and as such no voting rights of treasury shares have been exercised at the EGM. There were no repurchased Shares which are pending cancellation and should therefore be excluded from the total number of Shares in issue for the purposes of the EGM. There was no restriction on any shareholders of the Company (the “**Shareholder(s)**”) casting votes on any of the proposed resolutions at the EGM. No Shareholders were required under the Listing Rules to abstain from voting on any of the resolutions at the EGM and no Shareholders were entitled to attend and abstain from voting in favour as set out in rule 13.40 of the Listing Rules. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the EGM. All directors of the Company attended the EGM either in person or by electronic means.

The Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

The poll results in respect of the respective resolutions proposed at the EGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	(a) to give effect to and administer the 2025 Share Option Scheme as contemplated and in accordance with the 2025 Share Option Scheme Rules;	1,051,584,000 99.995436%	48,000 0.004564%
	(b) to allot, issue or otherwise deal in new Shares of the Company and to make or grant offers and agreements under the terms of the 2025 Share Option Scheme Rules and rules of any other share schemes (as defined in Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) adopted by the Company pursuant to Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited which is then operational, which would or might require the exercise of such powers be generally and unconditionally approved; provided that the aggregate number of Shares allotted or agreed conditionally or unconditionally to be allotted by the directors of the Company or their designated committee pursuant to the approval in this resolution in respect of all the share options to be granted under all share schemes of the Company (the “ Scheme Mandate Limit ”), shall not exceed in aggregate 10% of the Shares in issue (excluding treasury shares) at the date of passing of this resolution or the relevant date of approval of the refreshment of the Scheme Mandate Limit; and	1,051,584,000 99.995436%	48,000 0.004564%
	(c) conditional upon the 2025 Share Option Scheme becoming effective, the existing share option scheme of the Company, adopted on 1 February 2016 and effective from 10 March 2016, and is hereby terminated upon the 2025 Share Option Scheme coming into effect (without prejudice to the rights and benefits of and attached to any outstanding options which have been granted under the 2016 Share Option Scheme prior to the date hereof (if any)).	1,051,584,000 99.995436%	48,000 0.004564%

Note: Please refer to the Notice for the full text of the resolutions.

As more than 50% of votes were cast in favour of each of the resolutions 1(a) to 1(c), all the above ordinary resolutions were duly passed at the EGM.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 26 May 2025

As at the date of this announcement, the executive Directors are Mr. Huang Xiangbin, Mr. Lei Shifeng and Mr. Huang Zhijian; the non-executive Director is Ms. Jing Huan; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.